An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer

Trial ID # NCT01653912
Phase I/II
Drug Class Signaling Pathway Inhibitors: PI3K-AKT-mTOR/AKT
Drug Name Afuresertib
Alternate Drug Names GSK2110183
Drugs in Trial Afuresertib, Carboplatin, Paclitaxel
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

59 [escalation: 29; expansion: 30; median 3.8 prior therapies (1-10)]

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, PFS, evaluated per RECIST


ORR: 32.1% (2CR, 7PR, n=28)
DCR: 71.4% (2CR, 7PR, 11SD, n=28)
PFS: 7.1 months

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE: diarrhea (20%), rash (17%), fatigue (13%), vomiting (10%), anemia (10%)


Afuresertib mediated AKT kinase inhibition in combination with carboplatin+paclitaxel demonstrates promising efficacy in platinum resistant ovarian cancer


Blagden SP et al. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clin Cancer Res (2019) 25(5):1472-1478

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.